ClinicalTrials.gg
CompletedNCT05568615Updated Jul 21, 2026Results posted

Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS

A Phase 3 interventional study of MT-1186 in ALS, sponsored by Shionogi. Completed at 11 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Shionogi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety of oral edaravone at a dose of 105 mg administered once daily for 10 days out of a 14-day period, followed by a 14-day drug-free period. This study will be continued until the earlier date when oral edaravone is commercially available at each site in Japan or August 2023.

02

Conditions studied

  • ALS
03

In context

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must provide a signed and dated form (ICF) to participate in the study.
  • Subjects must be able (in the judgment of the Investigator) to understand the nature of the study and all risks involved with participation in the study
  • Subjects must be willing to cooperate and comply with all protocol restrictions and requirements.
  • Subjects who successfully complete Week 96 of Study MT-1186-A03 or Week 48 of Study MT-1186-A04 and have been compliant with study drug (80-120%).

Exclusion criteria

Exclusion Criteria:

  • Subjects of unwilling to use a highly effective method of from the Visit #1 until 3 months after the last dose of study medication.
  • Subjects who have a significant risk of suicide. Subjects with any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without a specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the C-SSRS at Week 96 of the A03 study or at Week 48 of the A04 study.
  • Subjects who are not eligible to continue in the study, as judged by the Investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    MT-1186 orally

    Subjects receive the edaravone oral suspension orally once daily for 10 days out of a 14-day period, followed by a 14-day drug-free period.

    Drug: MT-1186

Interventions

  • Suspension

    Also known as: Edaravone

06

What researchers measure

Primary outcomes

  1. Number of Patients With AEs and Adverse Drug Reactions

    Adverse Event (AE) is classified as treatment emergent if it newly occurred after the first dose of investigational product or if a pre-dose event increases in severity following the first dose of investigational product. Adverse Drug Reaction (ADR) is a noxious and unintended response to a medicinal product that occurs at doses normally used for prophylaxis, diagnosis, or therapy of disease.

    Time frame: up to 8 months

Other outcomes

  1. ALSFRS-R Total Score

    The ALSFRS-R is rating scale (ratings 0 = can't do, to 4 = normal ability) used to determine participants' assessment of their capability and independence in 12 functional activities.

    Time frame: up to 10 months or 31/Aug/2023

  2. Number of Death, Tracheostomy, or Permanent Assisted Mechanical Ventilation (≥23 Hours/Day)

    Time frame: up to 10 months or 31/Aug/2023

07

Results

Posted Feb 3, 2025

Participant flow

Participant flow — Overall Study
MilestoneMT-1186
Started15
Completed13
Not completed2
Withdrew: Death1
Withdrew: Physician decision1

Outcome measures

PrimaryNumber of Patients With AEs and Adverse Drug Reactions

Adverse Event (AE) is classified as treatment emergent if it newly occurred after the first dose of investigational product or if a pre-dose event increases in severity following the first dose of investigational product. Adverse Drug Reaction (ADR) is a noxious and unintended response to a medicinal product that occurs at doses normally used for prophylaxis, diagnosis, or therapy of disease.

Time frame:
up to 8 months
Reported as:
Count of participants · Participants
Number of Patients With AEs and Adverse Drug Reactions
ParticipantsMT-1186
Number of patients with AEs6
Number of patients with adverse drug reactions0
Other pre-specifiedALSFRS-R Total Score

The ALSFRS-R is rating scale (ratings 0 = can't do, to 4 = normal ability) used to determine participants' assessment of their capability and independence in 12 functional activities.

Time frame:
up to 10 months or 31/Aug/2023

Results for this outcome have not been posted.

Other pre-specifiedNumber of Death, Tracheostomy, or Permanent Assisted Mechanical Ventilation (≥23 Hours/Day)
Time frame:
up to 10 months or 31/Aug/2023

Results for this outcome have not been posted.

Adverse events

Collected over up to 8 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MT-11861/15 (6.7%)2/15 (13.3%)5/15 (33.3%)
Most frequent serious events
Most frequent serious events
EventMT-1186
Pneumonia aspirationInfections and infestations1/15
Respiratory failureRespiratory, thoracic and mediastinal disorders1/15
Most frequent other events
Most frequent other events
EventMT-1186
Otitis externaInfections and infestations1/15
Tinea crurisInfections and infestations1/15
ConstipationGastrointestinal disorders1/15
EczemaSkin and subcutaneous tissue disorders1/15
Decubitus ulcerSkin and subcutaneous tissue disorders1/15
Catheter site granulomaGeneral disorders1/15
Blood creatine phosphokinase increasedInvestigations1/15
Vital capacity decreasedInvestigations1/15
ContusionInjury, poisoning and procedural complications1/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)MT-1186
Mean59.3 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)MT-1186
Female6
Male9
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MT-1186
Hispanic or Latino0
Not Hispanic or Latino15
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MT-1186
White0
Black or African American0
Asian - Japanese15
Asian - Not Japanese0
American Indian or Alaska Native0
Native Hawaiian or Other Pacific Islander0
08

Study locations

11 sites
  • National Hospital Organization Higashinagoya National Hospital
    Nagoya, Aichi-ken 465-8620, Japan
  • National Hospital Organization Chibahigashi National Hospital
    Chiba, Chiba 260-8712, Japan
  • Fukushima Medical University Hospital
    Fukushima, Fukushima 960-1295, Japan
  • Kagawa University Hospital
    Kita-gun, Kagawa-ken 761-0793, Japan
  • Kitasato University Hospital
    Sagamihara-shi, Kanagawa 252-0375, Japan
  • Yokohama City University Hospital
    Yokohama, Kanagawa 236-0004, Japan
  • National Hospital Organization Kumamoto Saishun Medical Center
    Kōshi, Kumamoto 861-1196, Japan
  • National Hospital Organization Osaka Toneyama Medical Center
    Toyonaka-shi, Osaka 560-8552, Japan
  • Shiga University of Medical Science Hospital
    Ōtsu, Shiga 520-2192, Japan
  • Tokyo Metropolitan Neurological Hospital
    Fuchu-shi, Tokyo 183-0042, Japan
  • National Epilepsy Center NHO Shizuoka Institute of Epilepsy and Neurological Disorders
    Shizuoka, 420-8688, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Jun 2023, 8 months.

Results were first posted in Feb 2025, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2022
First posted
Oct 5, 2022
StartActual
Oct 26, 2022
Primary completionActual
Jun 27, 2023
CompletionActual
Jun 27, 2023
Results first posted
Feb 3, 2025
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05568615
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Oct 5, 2022
Start date
Oct 26, 2022
Primary completion
Jun 27, 2023
Completion
Jun 27, 2023
Results posted
Feb 3, 2025
Last update
Jul 21, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion